Literature DB >> 33710015

HLA-associated preadaptation in HIV Vif is associated with higher set point viral load and faster CD4+ decline in Zambian transmission pairs.

Sarah Connolly1, Jonathan M Carlson2, Malinda Schaefer1, Alfred Bere1, William Kilembe3, Susan Allen3,4,5, Eric Hunter1,3,5.   

Abstract

OBJECTIVE S: We investigated the relationship between human leukocyte antigen (HLA)-associated preadaptation for the entire subtype C HIV-1 proteome of the transmitted founder virus and subsequent HIV-1 disease progression in a cohort of heterosexual linked transmission pairs in Zambia.
DESIGN: An adaptation model was used to calculate an adaptation score for each virus-HLA combination in order to quantify the degree of preadaptation of the transmitted virus to the linked recipient's HLA alleles. These scores were then assessed for their relationship to viral load and longitudinal CD4+ decline in the recipient.
METHODS: Viral RNA was extracted from the plasma of the donor partner and the linked recipient near the time of transmission, as well as longitudinally from the linked recipient. Viral adaptation scores were calculated for each individual and each protein in the subtype C HIV-1 proteome.
RESULTS: The majority of HLA-associated sites were located in Gag, Pol and Nef; however, proportional to protein length, the accessory and regulatory proteins contained a relatively high proportion of HLA-associated sites. Over the course of infection, HLA-mediated immune adaptation increased for all proteins except Vpu and gp120. Preadaptation was positively associated with higher early set point viral load and faster CD4+ decline. When examined by protein, preadaptation in Pol and Vif were statistically significantly associated with these markers of disease progression.
CONCLUSION: Adaptation in Pol had the greatest impact on viral control. Despite containing a large proportion of HLA-associated sites, Vif was the only regulatory or accessory protein for which preadaptation significantly correlated with disease progression.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33710015      PMCID: PMC8546905          DOI: 10.1097/QAD.0000000000002868

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  32 in total

1.  Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.

Authors:  Jaclyn K Wright; Vanessa L Naidoo; Zabrina L Brumme; Jessica L Prince; Daniel T Claiborne; Philip J R Goulder; Mark A Brockman; Eric Hunter; Thumbi Ndung'u
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 2.  HIV and HLA class I: an evolving relationship.

Authors:  Philip J R Goulder; Bruce D Walker
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

3.  Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Authors:  Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Authors:  Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

5.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

6.  Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.

Authors:  Jessica L Prince; Daniel T Claiborne; Jonathan M Carlson; Malinda Schaefer; Tianwei Yu; Shabir Lahki; Heather A Prentice; Ling Yue; Sundaram A Vishwanathan; William Kilembe; Paul Goepfert; Matthew A Price; Jill Gilmour; Joseph Mulenga; Paul Farmer; Cynthia A Derdeyn; Jiaming Tang; David Heckerman; Richard A Kaslow; Susan A Allen; Eric Hunter
Journal:  PLoS Pathog       Date:  2012-11-29       Impact factor: 6.823

7.  Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.

Authors:  Zabrina L Brumme; Chanson J Brumme; David Heckerman; Bette T Korber; Marcus Daniels; Jonathan Carlson; Carl Kadie; Tanmoy Bhattacharya; Celia Chui; James Szinger; Theresa Mo; Robert S Hogg; Julio S G Montaner; Nicole Frahm; Christian Brander; Bruce D Walker; P Richard Harrigan
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

8.  HIV testing and counselling couples together for affordable HIV prevention in Africa.

Authors:  Kristin M Wall; Mubiana Inambao; William Kilembe; Etienne Karita; Bellington Vwalika; Joseph Mulenga; Rachel Parker; Tyronza Sharkey; Divya Sonti; Amanda Tichacek; Eric Hunter; Robert Yohnka; Joseph F Abdallah; Ibou Thior; Julie Pulerwitz; Susan Allen
Journal:  Int J Epidemiol       Date:  2019-02-01       Impact factor: 7.196

9.  Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery.

Authors:  Matt A Price; William Kilembe; Eugene Ruzagira; Etienne Karita; Mubiana Inambao; Eduard J Sanders; Omu Anzala; Susan Allen; Vinodh A Edward; Pontiano Kaleebu; Patricia E Fast; Wasima Rida; Anatoli Kamali; Eric Hunter; Jianming Tang; Shabir Lakhi; Gaudensia Mutua; Linda Gail Bekker; Ggayi Abu-Baker; Amanda Tichacek; Paramesh Chetty; Mary H Latka; Pholo Maenetje; Heeran Makkan; Jonathan Hare; Freddie Kibengo; Fran Priddy; Elise Landais; Kundai Chinyenze; Jill Gilmour
Journal:  Int J Epidemiol       Date:  2021-03-03       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.